Targeting poly(ADP-ribose) polymerase: A two-armed strategy for cancer therapy

Clinical Cancer Research

Volumn 13, Issue 21, 2007, Pages 6252-6256

  Plummer, Elizabeth Ruth ^a,b   Calvert, Hilary ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 888; AG 014699; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CEP 6800; CISPLATIN; DOUBLE STRANDED DNA; GP 21016; GPI 15427; GPI 21016; INO 1001; IRINOTECAN; KU 0059436; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; QUINAZOLINE DERIVATIVE; SINGLE STRANDED DNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; CELL PROTECTION; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; EXCISION REPAIR; GENOME; HOST; HUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; DNA DAMAGE; DNA REPAIR; GENOME; GENOME, HUMAN; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 35948968410     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0617     Document Type: Article

References (55)

1. Chambon P, Weil J, Mandel P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 1963;11:39.
2. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002;45:73-85.
3. Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005;52:109-18.
4. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
5. Bernstein C, Bernstein H, Payne CM, Garewal H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res 2002;511:145-78.
6. Christmann M, Tomicic MT, Roos WP, Kaina B. Mechanisms of human DNA repair: an update. Toxicology 2003;193:3-34.
7. Dantzer F, de La Rubia G, Menissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking poly(ADP-ribose) polymerase-1. Biochemistry 2000;39:7559-69.
8. D'Silva I, Pelletier JD, Lagueux J, et al. Relative affinities of poly(ADP-ribose) polymerase and DNA-dependent protein kinase for DNA strand interruptions. Biochim Biophys Acta 1999;1430:119-26.
9. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004;279:55117-26.
10. Audebert M, Salles B, Weinfeld M, Calsou P. Involvement of polynucleotide kinase in a poly(ADP-ribose) polymerase-1-dependent DNA double-strand breaks rejoining pathway. J Mol Biol 2006;356:257-65.
11. Wang M, Wu W, Rosidi B, Zhang L, Wang H, Iliakis G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 2006;34:6170- 82.
12. de Murcia G, Menissier de Murcia J. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 1994;19:172-6.
13. Davidovic L, Vodenicharov M, Affar EB, Poirier GG. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp Cell Res 2001;268:7-13.
14. Masutani M, Nozaki T, Nishiyama E, et al. Function of poly(ADP-ribose) polymerase in response to DNA damage: gene-disruption study in mice. Mol Cell Biochem 1999;193:149-52.
15. Althaus FR, Kleczkowska HE, Malanga M, et al. Poly ADP-ribosylation: a DNA break signal mechanism. Mol Cell Biochem1999;193:5-11.
16. Satoh MS, Lindahl T. Role of poly(ADP-ribose) formation in DNA repair. Nature 1992;356:356 -8.
17. Simonin F. The carboxy-terminal domain of human poly(ADP-ribose) polymerase. Overproduction in Escherichia coli large scale purification and characterization. J Biol Chem1993;268:13454-61.
18. Purnell MR, Whish WJD. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem J 1980;185:775-7.
19. + binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 1998;37:3893-900.
20. Canan Koch SS, Thoresen LH, Tikhe JG, et al. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J Med Chem 2002;45:4961-74.
21. Skalitzky DJ, Marakovits JT, Maegley KA, et al. Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors. J Med Chem 2003;46:210-3.
22. Tikhe JG, Webber SE, Hostomsky Z, et al. Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J Med Chem 2004;47:5467-81.
23. Southan GJ, Szabo C. Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 2003;10:321-40.
24. Griffin RJ, Pemberton LC, Rhodes D, et al. Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP). Anticancer Drug Des 1995;10:507-14.
25. Ames BN, Gold LS. Endogenous mutagens and the causes of aging and cancer. Mutat Res 1991;250:3-16.
26. Hansen K, Kelly M. Review of mammalian DNA repair and translational implications. J Pharmacol Exp Ther 2000;295:1-9.
27. Lindahl T, Karran P, Wood RD. DNA excision repair pathways. Curr Opin Genet Dev 1997;7:158-69.
28. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 1998;18:3563-71.
29. Durkacz B, Omidiji O, Gray D, Shall S. (ADP-ribose) n participates in DNA excision repair. Nature 1980;283:593-6.
30. Andreassen P, Ho G, D'Andrea A. DNA damage responses and their many interactions with the replication fork. Carcinogenesis 2006;27:883-92.
31. Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br J Cancer 1998;78:1269-77.
32. Calabrese CR, Batey MA, Thomas HD, et al. Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res 2003;9:2711-8.
33. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2 :371-82.
34. Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005;52:25-33.
35. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
36. Tutt AN, Lord CJ, McCabe N, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005;70:139-48.
37. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005;205:275-92.
38. Hoeijmakers JH. Genone maintenance mechanisms for preventing cancer. Nature 2001;411:360-74.
39. Boulton S, Pemberton LC, Porteous JK, et al. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(-ADP-ribose) polymerase inhibitors. Br J Cancer 1995;72:849-56.
40. Delaney CA, Wang LZ, Kyle S, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000;6:2860-7.
41. Tentori L, Leonetti C, Scarsella M, et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 2003;9:5370-9.
42. Cheng CL, Johnson SP, Keir ST, et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 2005;4:1364-8.
43. Plummer R, Middleton M, Wilson R, et al. First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. J Clin Oncol 2005;23:208S.
44. Plummer R, Lorigan P, Evans J, et al. First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol 2006;24:8013.
45. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004;10:1871- 4.
46. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
47. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
48. Tentori L, Leonetti C, Scarsella M, et al. Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int J Oncol 2005;26:415-22.
49. Tentori L, Portarena I, Torino F, Scerrati M, Navarra P, Graziani G. Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells. Glia 2002;40:44-54.
50. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004;96:56-67.
51. Fong P, Spicer J, Reade S, et al. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of poly ADP-ribose polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. J Clin Oncol 2006;24:3022.
52. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.
53. Turner N, Tutt A, Ashworth A. Hallmarks of BRCA-ness in sporadic cancer. Nat Rev Cancer 2004;4:814-9.
54. Plummer ER. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr Opin Pharmacol 2006;6:364-8.
55. Ratman K, Low J. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007;13:1383-8.